Compare Abeona Therapeutics Inc (ABEO) vs Centrus Energy Corp (LEU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Centrus Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Centrus Energy Corp trades at $165.57 (market cap $3.26B). The key difference: Centrus Energy Corp is far larger — about 8.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | LEU | |
|---|---|---|
Market Cap | $373.32M | $3.26B |
Sector | Health | Energy |
52-Week High | $7.23 | $436.00 |
52-Week Low | $4.17 | $146.61 |
Enterprise Value | $228.22M | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Centrus Energy (LEU) trades at $174.23, up 7.46% today, with mixed technical signals showing neutral momentum. The company reported strong Q1 2026 earnings beat but faces valuation concerns with a P/E of 63.36. Recent catalysts include a $900 million DOE contract and inclusion in the S&P SmallCap 600 index, positioning LEU as the sole U.S.-licensed HALEU producer amid growing nuclear energy demand.
LEU offers exposure to U.S. nuclear fuel supply chain growth with $3.9 billion contracted backlog, but high valuation and execution risks warrant caution. Analyst consensus targets $219.50 (26% upside) with no sell ratings, though recent earnings misses and declining 2026 profit margins highlight operational challenges. The stock's premium valuation requires sustained contract execution and margin improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
